Selected research
Industry Research
Antidiabetic Sulphonylureas Industry Research Report 2026
Market perspective
The global Antidiabetic Sulphonylureas market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Antidiabetic Sulphonylureas is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Antidiabetic Sulphonylureas is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Antidiabetic Sulphonylureas is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Antidiabetic Sulphonylureas include Boehringer Ingelheim, Bristol-Myers Squibb, Novo Nordisk, Servier Laboratories, AstraZeneca, GlaxoSmithKline, Pfizer, Eli Lilly and Merck & Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Antidiabetic Sulphonylureas market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antidiabetic Sulphonylureas Market by Company
Boehringer Ingelheim
Bristol-Myers Squibb
Novo Nordisk
Servier Laboratories
AstraZeneca
GlaxoSmithKline
Pfizer
Eli Lilly
Merck & Co
Sanofi
Takeda Pharmaceuticals
Antidiabetic Sulphonylureas Segment by Type
First Generation Antidiabetic Sulphonylureas
The Second Generation Antidiabetic Sulphonylureas
The Third Generation Antidiabetic Sulphonylureas
Antidiabetic Sulphonylureas Segment by Application
Hospitals
Clinics
Other
Antidiabetic Sulphonylureas Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antidiabetic Sulphonylureas market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antidiabetic Sulphonylureas and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antidiabetic Sulphonylureas.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Antidiabetic Sulphonylureas manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Antidiabetic Sulphonylureas by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Antidiabetic Sulphonylureas in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- First Generation Antidiabetic Sulphonylureas
- The Second Generation Antidiabetic Sulphonylureas
- The Third Generation Antidiabetic Sulphonylureas
Applications
- Hospitals
- Clinics
- Other
Companies covered
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Novo Nordisk
- Servier Laboratories
- AstraZeneca
- GlaxoSmithKline
- Pfizer
- Eli Lilly
- Merck & Co
- Sanofi
- Takeda Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Antidiabetic Sulphonylureas Market Size (2021-2032)
- 2.2.2 Global Antidiabetic Sulphonylureas Sales (2021-2032)
- 2.2.3 Global Antidiabetic Sulphonylureas Market Average Price (2021-2032)
- 2.3 Antidiabetic Sulphonylureas by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 First Generation Antidiabetic Sulphonylureas
- 2.3.3 The Second Generation Antidiabetic Sulphonylureas
- 2.3.4 The Third Generation Antidiabetic Sulphonylureas
- 2.4 Antidiabetic Sulphonylureas by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Antidiabetic Sulphonylureas Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Antidiabetic Sulphonylureas Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Antidiabetic Sulphonylureas Revenue of Manufacturers (2021-2026)
- 3.4 Global Antidiabetic Sulphonylureas Average Price by Manufacturers (2021-2026)
- 3.5 Global Antidiabetic Sulphonylureas Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Antidiabetic Sulphonylureas, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Antidiabetic Sulphonylureas, Product Type & Application
- 3.8 Global Manufacturers of Antidiabetic Sulphonylureas, Established Date
- 3.9 Global Antidiabetic Sulphonylureas Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Boehringer Ingelheim
- 4.1.1 Boehringer Ingelheim Company Information
- 4.1.2 Boehringer Ingelheim Business Overview
- 4.1.3 Boehringer Ingelheim Antidiabetic Sulphonylureas Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Boehringer Ingelheim Antidiabetic Sulphonylureas Product Portfolio
- 4.1.5 Boehringer Ingelheim Recent Developments
- 4.2 Bristol-Myers Squibb
- 4.2.1 Bristol-Myers Squibb Company Information
- 4.2.2 Bristol-Myers Squibb Business Overview
- 4.2.3 Bristol-Myers Squibb Antidiabetic Sulphonylureas Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bristol-Myers Squibb Antidiabetic Sulphonylureas Product Portfolio
- 4.2.5 Bristol-Myers Squibb Recent Developments
- 4.3 Novo Nordisk
- 4.3.1 Novo Nordisk Company Information
- 4.3.2 Novo Nordisk Business Overview
- 4.3.3 Novo Nordisk Antidiabetic Sulphonylureas Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novo Nordisk Antidiabetic Sulphonylureas Product Portfolio
- 4.3.5 Novo Nordisk Recent Developments
- 4.4 Servier Laboratories
- 4.4.1 Servier Laboratories Company Information
- 4.4.2 Servier Laboratories Business Overview
- 4.4.3 Servier Laboratories Antidiabetic Sulphonylureas Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Servier Laboratories Antidiabetic Sulphonylureas Product Portfolio
- 4.4.5 Servier Laboratories Recent Developments
- 4.5 AstraZeneca
- 4.5.1 AstraZeneca Company Information
- 4.5.2 AstraZeneca Business Overview
- 4.5.3 AstraZeneca Antidiabetic Sulphonylureas Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AstraZeneca Antidiabetic Sulphonylureas Product Portfolio
- 4.5.5 AstraZeneca Recent Developments
- 4.6 GlaxoSmithKline
- 4.6.1 GlaxoSmithKline Company Information
- 4.6.2 GlaxoSmithKline Business Overview
- 4.6.3 GlaxoSmithKline Antidiabetic Sulphonylureas Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 GlaxoSmithKline Antidiabetic Sulphonylureas Product Portfolio
- 4.6.5 GlaxoSmithKline Recent Developments
- 4.7 Pfizer
- 4.7.1 Pfizer Company Information
- 4.7.2 Pfizer Business Overview
- 4.7.3 Pfizer Antidiabetic Sulphonylureas Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer Antidiabetic Sulphonylureas Product Portfolio
- 4.7.5 Pfizer Recent Developments
- 4.8 Eli Lilly
- 4.8.1 Eli Lilly Company Information
- 4.8.2 Eli Lilly Business Overview
- 4.8.3 Eli Lilly Antidiabetic Sulphonylureas Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Eli Lilly Antidiabetic Sulphonylureas Product Portfolio
- 4.8.5 Eli Lilly Recent Developments
- 4.9 Merck & Co
- 4.9.1 Merck & Co Company Information
- 4.9.2 Merck & Co Business Overview
- 4.9.3 Merck & Co Antidiabetic Sulphonylureas Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Merck & Co Antidiabetic Sulphonylureas Product Portfolio
- 4.9.5 Merck & Co Recent Developments
- 4.10 Sanofi
- 4.10.1 Sanofi Company Information
- 4.10.2 Sanofi Business Overview
- 4.10.3 Sanofi Antidiabetic Sulphonylureas Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sanofi Antidiabetic Sulphonylureas Product Portfolio
- 4.10.5 Sanofi Recent Developments
- 4.11 Takeda Pharmaceuticals
- 4.11.1 Takeda Pharmaceuticals Company Information
- 4.11.2 Takeda Pharmaceuticals Business Overview
- 4.11.3 Takeda Pharmaceuticals Antidiabetic Sulphonylureas Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Takeda Pharmaceuticals Antidiabetic Sulphonylureas Product Portfolio
- 4.11.5 Takeda Pharmaceuticals Recent Developments
5 Global Antidiabetic Sulphonylureas Market Scenario by Region
- 5.1 Global Antidiabetic Sulphonylureas Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Antidiabetic Sulphonylureas Sales by Region: 2021-2032
- 5.2.1 Global Antidiabetic Sulphonylureas Sales by Region: 2021-2026
- 5.2.2 Global Antidiabetic Sulphonylureas Sales by Region: 2027-2032
- 5.3 Global Antidiabetic Sulphonylureas Revenue by Region: 2021-2032
- 5.3.1 Global Antidiabetic Sulphonylureas Revenue by Region: 2021-2026
- 5.3.2 Global Antidiabetic Sulphonylureas Revenue by Region: 2027-2032
- 5.4 North America Antidiabetic Sulphonylureas Market Facts & Figures by Country
- 5.4.1 North America Antidiabetic Sulphonylureas Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Antidiabetic Sulphonylureas Sales by Country (2021-2032)
- 5.4.3 North America Antidiabetic Sulphonylureas Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Antidiabetic Sulphonylureas Market Facts & Figures by Country
- 5.5.1 Europe Antidiabetic Sulphonylureas Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Antidiabetic Sulphonylureas Sales by Country (2021-2032)
- 5.5.3 Europe Antidiabetic Sulphonylureas Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Antidiabetic Sulphonylureas Market Facts & Figures by Country
- 5.6.1 Asia Pacific Antidiabetic Sulphonylureas Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Antidiabetic Sulphonylureas Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Antidiabetic Sulphonylureas Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Antidiabetic Sulphonylureas Market Facts & Figures by Country
- 5.7.1 South America Antidiabetic Sulphonylureas Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Antidiabetic Sulphonylureas Sales by Country (2021-2032)
- 5.7.3 South America Antidiabetic Sulphonylureas Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Antidiabetic Sulphonylureas Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Antidiabetic Sulphonylureas Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Antidiabetic Sulphonylureas Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Antidiabetic Sulphonylureas Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Antidiabetic Sulphonylureas Sales by Type (2021-2032)
- 6.1.1 Global Antidiabetic Sulphonylureas Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Antidiabetic Sulphonylureas Sales Market Share by Type (2021-2032)
- 6.2 Global Antidiabetic Sulphonylureas Revenue by Type (2021-2032)
- 6.2.1 Global Antidiabetic Sulphonylureas Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Antidiabetic Sulphonylureas Revenue Market Share by Type (2021-2032)
- 6.3 Global Antidiabetic Sulphonylureas Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Antidiabetic Sulphonylureas Sales by Application (2021-2032)
- 7.1.1 Global Antidiabetic Sulphonylureas Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Antidiabetic Sulphonylureas Sales Market Share by Application (2021-2032)
- 7.2 Global Antidiabetic Sulphonylureas Revenue by Application (2021-2032)
- 7.2.1 Global Antidiabetic Sulphonylureas Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Antidiabetic Sulphonylureas Revenue Market Share by Application (2021-2032)
- 7.3 Global Antidiabetic Sulphonylureas Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Antidiabetic Sulphonylureas Value Chain Analysis
- 8.1.1 Antidiabetic Sulphonylureas Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Antidiabetic Sulphonylureas Production Mode & Process
- 8.2 Antidiabetic Sulphonylureas Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Antidiabetic Sulphonylureas Distributors
- 8.2.3 Antidiabetic Sulphonylureas Customers
9 Global Antidiabetic Sulphonylureas Analyzing Market Dynamics
- 9.1 Antidiabetic Sulphonylureas Industry Trends
- 9.2 Antidiabetic Sulphonylureas Industry Drivers
- 9.3 Antidiabetic Sulphonylureas Industry Opportunities and Challenges
- 9.4 Antidiabetic Sulphonylureas Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst